Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis

Aggio, RGM, White, P, Jayasena, H, Lacy Costello, B, Ratcliffe, NM and Probert, CSJ ORCID: 0000-0003-4550-0239
(2016) Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis. Alimentary Pharmacology and Therapeutics, 45 (1). 82 - 90.

[img] Text
AggioEtAl_R4-APTIBSIBD.docx - Accepted Version

Download (62kB)
[img] Text
Figure1New.pdf - Accepted Version

Download (307kB)
[img] Text
Figure2New.pdf - Accepted Version

Download (205kB)
[img] Text
FigureS3New.pdf - Accepted Version

Download (547kB)
[img] Text
NewFigureS1.pdf - Accepted Version

Download (627kB)


Background Inflammatory bowel disease and irritable bowel syndrome may present in a similar manner. Measuring faecal calprotectin concentration is often recommended to rule out inflammatory bowel disease, however, there are no tests to positively diagnose irritable bowel syndrome and invasive tests are still used to rule out other pathologies. Aim To investigate a platform technology for diagnosing inflammatory bowel disease and irritable bowel syndrome based on faecal gas. Methods The platform technology is composed of a gas chromatography column coupled to a metal oxide gas sensor (OdoReader) and a computer algorithm. The OdoReader separates the volatile compounds from faecal gas and the computer algorithm identifies resistance patterns associated with specific medical conditions and builds classification models. This platform was applied to faecal samples from 152 patients: 33 patients with active inflammatory bowel disease; 50 patients with inactive inflammatory bowel disease; 28 patients with irritable bowel syndrome and 41 healthy donors (Control). Results The platform classified samples with accuracies from 75% to 100% using rigorous validation schemes: namely leave‐one‐out cross‐validation, 10‐fold cross‐validation, double cross‐validation and their Monte Carlo variations. The most clinically important findings, after double cross‐validation, were the accuracy of active Crohn's disease vs. irritable bowel syndrome (87%; CI 84–89%) and irritable bowel syndrome vs. controls (78%; CI 76–80%). These schemes provide an estimate of out‐of‐sample predictive accuracy for similar populations. Conclusions This is the first description of an investigation for the positive diagnosis of irritable bowel syndrome, and for diagnosing inflammatory bowel disease.

Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 22 Nov 2016 15:02
Last Modified: 19 Feb 2021 11:59
DOI: 10.1111/apt.13822
Related URLs: